


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+1.61%
+2.74%
+0.46%
+0.52%
-3.04%
BIIB
Biogen
$196.52
Strengths

Trading below its fair value
Risk Analysis

Earnings are forecast to decrease
BIIB Price Performance
$165.38 (+18.83%)
$168.21 (+16.83%)
$139.31 (+41.07%)
$139.31 (+41.07%)
Overall standing based on market and analyst consensus.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates

Earnings decline YoY
Rating
Rating
Momentum
Momentum

Has been gaining momentum
Activity
Activity
Future
Future

Earnings are forecast to decrease

Trading below its fair value
![]()
BIIB Analysts opinion is positive but there was a setback from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
BIIB Street Sentiment is bullish and have positive views on the near-term outlook
BIIB has Low risk level

Average key support and resistance price levels
Recent Upgrades and Downgrades
BUY
Date
Action
Rating
Firm
Nov 22, 2025
Reiterate
Neutral
Piper Sandler
Nov 07, 2025
Upgrade
Buy
Stifel
Nov 01, 2025
Reiterate
Outperform
RBC
Sep 25, 2025
Initiate
Buy
Jefferies
Sep 25, 2025
Upgrade
Neutral
Goldman Sachs
AMGN
Amgen
369.19
+1.52%
CHRS
Coherus BioSciences
1.61
-19.90%
BNTX
BioNTech
105.87
+0.10%
ALVO
Alvotech
4.64
-1.49%
What is BIIB current stock price?
What are BIIB stock strengths?
What is BIIB Risk Level?
What is BIIB market cap and volume?
What is BIIB current Stock IQ?
Should I buy BIIB stock right now?
Is BIIB a Strong Buy right now?
What does a 'Strong Buy' rating mean for BIIB?
What does a 'Strong Sell' rating mean for BIIB?
What factors influence BIIB's Stock IQ?
Join our subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+1.61%
+2.74%
+0.46%
+0.52%
-3.04%
BIIB
Biogen
Current Price
$196.52
Runners Also Watch
AMGN
Amgen
369.19
+1.52%
CHRS
Coherus BioSciences
1.61
-19.90%
BNTX
BioNTech
105.87
+0.10%
ALVO
Alvotech
4.64
-1.49%

BIIB Price Performance
$165.38 (+18.83%)
$168.21 (+16.83%)
$139.31 (+41.07%)
$139.31 (+41.07%)
BIIB Analysts Opinion
Overall standing per market and analyst expectations.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates

Earnings decline YoY
Rating
Rating
Momentum
Momentum

Has been gaining momentum
Activity
Activity
Future
Future

Earnings are forecast to decrease

Trading below its fair value
![]()
BIIB Analysts opinion is positive but there was a setback from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
BIIB Street Sentiment is bullish and have positive views on the near-term outlook
BIIB has Low risk level

Average key support and resistance price levels
Overall Wall Street Rating
BUY
Nov 22, 2025
Reiterate
Neutral
Piper Sandler
Nov 07, 2025
Upgrade
Buy
Stifel
Nov 01, 2025
Reiterate
Outperform
RBC
Sep 25, 2025
Initiate
Buy
Jefferies
Sep 25, 2025
Upgrade
Neutral
Goldman Sachs
BIIB Stock IQ
Stock Insights
Strengths

Trading below its fair value
Risk Analysis

Earnings are forecast to decrease
BIIB Latest Analysis
Biogen Inc. (BIIB) Presents at Piper Sandler Virtual Novel Targets in Immunology Symposium Transcript.
Fri Feb 13, 2026
Wedbush Lifts PT on Biogen Inc. (BIIB) to $187 From $178 – Heres Why. Biogen Inc. (NASDAQ:BIIB) is one of the best medical research stocks to buy according to hedge funds. On February 10 Wedbush lifted the price target on Biogen Inc. (NASDAQ:BIIB) to $187 from $178 maintaining a Neutral rating on the shares. The firm told investors that Biogen Inc. (NASDAQ:BIIB) delivered another top-/bottom-line beat in its fiscal Q4 [….]
Fri Feb 13, 2026
Biogen Announces Board Chair Transition. Caroline Dorsa to retire from the Biogen Board of Directors. Dr. Maria C. Freire Director since 2021 elected as new Chair
Wed Feb 11, 2026
Biogen Inc. (BIIB) Q4 Earnings and Revenues Top Estimates. Biogen (BIIB) delivered earnings and revenue surprises of 23.40% and 3.06% respectively for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Fri Feb 6, 2026
Biogen Q4 Results Top Estimates. Guides FY26 Adj. EPS Above Estimates . (RTTNews) - Biotechnology company Biogen Inc. (BIIB) reported Friday a net loss attributable to the company for the fourth quarter of $48.9 million or $0.33 per share compared to net income of $266.8 million or $1.83 per share in the prior-year quarter.
Fri Feb 6, 2026
Analysts Estimate Biogen Inc. (BIIB) to Report a Decline in Earnings: What to Look Out for. Biogen (BIIB) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Fri Jan 30, 2026
Biogen Says FDA Grants Breakthrough Therapy Designation For Litifilimab To Treat CLE . (RTTNews) - Biogen Inc. (BIIB) announced Wednesday that the United States Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for litifilimab (BIIB059) for the treatment of cutaneous lupus erythematosus (CLE).
Wed Jan 28, 2026
FIND US ON
Unlock the knowledge that 5,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
BIIB Stock trends
BIIB Stock performance
BIIB Stock analysis
BIIB investment strategies
Disclaimer:
The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained.
The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.